As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.
Last month, during a forum organized by US News & World Report, Amy Caro, vice president of health IT programs at Northrop
Northrop Grumman received the award under the BioWatch Gen-3 System Performance Demonstration Contract, and said that the contract could be worth up to $37 million over three years.
Agilent Technologies, Columbia University, and others are collaborating on development of the system, which will be based on MassTag PCR.
The firms won grants to develop integrated diagnostic systems used to counter natural or man-made biological threats.
The companies will use Luminex's xMAP technology to develop an automated biothreat detection tool for a US biosecurity network.
US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.
In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.